XSHE
300765
Market cap9.46bUSD
Oct 09, Last price
45.40CNY
1D
0.67%
1Q
17.31%
IPO
475.58%
Name
CSPC Innovation Pharmaceutical Co Ltd
Chart & performance
P/E
—
P/S
29.70
EPS
—
Div yield, %
0.04%
Shrs. gr., 5y
0.82%
Rev. gr., 5y
3.03%
Revenues
2.15b
+8.41%
Net income
-241m
L
CFO
-196m
L-84.16%
Dividend
May 29, 20250.02 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating from its base in Shijiazhuang, China, CSPC Innovation Pharmaceutical Co., Ltd. specializes in the manufacturing and commercialization of caffeine, vitamin C, health supplements, and various beverage offerings. The company functions as a subsidiary of the larger entity, CSPC Pharmaceutical Group Limited.
Key people
Long Dai
Chief Financial Officer, Secretary of the Board, Director · since 2024
Chairman of the Board, General Manager · since 2024
Xiwu Hui
Deputy General Manager · since 2025
Feng Han
Director · since 2024
Wen Xu
Director · since 2024
Congzhi Di
Independent Director · since 2023
Dibin Li
Independent Director · since 2023
Peng Yang
Independent Director · since 2023
Independent Director · since 2024
Headquarters & legal address
石家庄市栾城县富强西路36号
石家庄市, HE 050000
CN
石家庄市, HE 050000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||